Mostrando 4 resultados de: 4
Filtros aplicados
Subtipo de publicación
Article(4)
A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA"
ArticleAbstract: Background: The raising prevalence of type-2 diabetes mellitus and obesity has been recognized as aPalabras claves:Autores:Lahera V., Márquez G.A., PATRICIO LOPEZ -JARAMILLO, Pradilla L.P., Rueda-Clausen C.F., Silva-Sieger F.A.Fuentes:googlescopusDouble blind, randomized controlled trial, to evaluate the effectiveness of a controlled nitric oxide releasing patch versus meglumine antimoniate in the treatment of cutaneous leishmaniasis [NCT00317629]
ArticleAbstract: Background: Cutaneous Leishmaniasis is a worldwide disease, endemic in 88 countries, that has shownPalabras claves:Autores:Buitrago A., Díaz H., López M., Mosquera H., Muñoz G., PATRICIO LOPEZ -JARAMILLO, Rueda L.C., Rueda-Clausen C.F., Silva S.Y., Silva-Sieger F.A., Smith D.J., Vélez I.D.Fuentes:googlescopusDouble blind, randomized, placebo controlled clinical trial for the treatment of diabetic foot ulcers, using a nitric oxide releasing patch: PATHON
ArticleAbstract: Background: Diabetes Mellitus constitutes one of the most important public health problems due to itPalabras claves:Autores:Bhide M., Calderón C.A., Castillo J.C., Kampeerapappun P., López M., Márquez G.A., Matute J., Orduz A., PATRICIO LOPEZ -JARAMILLO, Rueda L.C., Rueda-Clausen C.F., Silva S.Y., Silva-Sieger F.A., Smith D.J.Fuentes:googlescopusRationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2×2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment
ArticleAbstract: Rationale: Controversy exists over the optimal dose of intravenous (iv) recombinant tissue plasminogPalabras claves:Acute ischaemic stroke, Alteplase, Dose, Hypertension, Rt-PA, thrombolysisAutores:Arima H., Bath P.M.W., Broderick J.P., Chalmers J., Chen X., Demchuk A.M., Donnan G.A., Fuentes S., Huang Y., Kim J.S., Lavados P.M., Lee T.H., Levi C., Lindley R.I., Martins S.O., Nguyen T.H., Octavio Marques Pontes-Neto, Olavarria V.V., Pandian J.D., Parsons M.W., Ricci S., Robinson T.G., S Anderson C., Sharma V.K., Silva-Sieger F.A., Stapf C., Wang J.G., Woodward M.Fuentes:scopus